Heparin, klotho, and FGF23: the 3-beat waltz of the discordant heart
Authors:
- 20 July 2022
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 102 (2) , 228-230
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01DK102815)
- National Institutes of Health (R01DK114158)
- Vifor Pharma
This publication has 8 references indexed in Scilit:
- Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2022
- FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in miceJournal of Molecular and Cellular Cardiology, 2020
- α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signallingNature, 2018
- FGF23 signaling impairs neutrophil recruitment and host defense during CKDJournal of Clinical Investigation, 2016
- Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular HypertrophyCell Metabolism, 2015
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006